Clinical Exome Sequencing Genetically Identifies Rare Mendelian Disorders

Clinical exome sequencing was conducted as trio-CES, both parents and their affected child sequenced simultaneously, to effectively detect de novo and compound heterozygous variants or as proband-CES with only the affected individual sequenced, when parental samples were not available.

Whole blood collected in tubes with anticoagulants or purified genomic DNA from tissue sources was accepted for testing. Genomic DNA extraction, library preparation, sequencing, and data analysis were performed using validated protocols. Exome capture was performed using SureSelect Human All Exon V2 Kit (Agilent Technologies; Santa Clara, CA, USA) and sequencing was performed using the HiSeq 2000 for a 50-bp paired-end run or HiSeq 2500 for a 100-bp paired-end run (Illumina; San Diego, CA, USA).

Of the 814 cases, the overall molecular diagnosis rate was 26%. The molecular diagnosis rate for trio-CES was 31% 1(27/410 cases), and 22% (74/338 cases) for proband-CES. In cases of developmental delay in 138 children, who were under five years of age, the molecular diagnosis rate was 41% (45/109), for trio-CES cases and 9% (2/23) for proband-CES cases. The significantly higher diagnostic yield of trio-CES was due to the identification of de novo and compound heterozygous variants.

Wayne W. Grody, MD, PhD, a professor of pathology and coauthor of the study, said, “All families deserve a clear diagnosis of their child's condition. Exome sequencing plays an important role in identifying the precise cause of a child's illness. This is immediately useful to families and physicians in understanding how the disease occurred, preventing unnecessary testing, and developing the best strategies to treat it.” The study was published on October 18, 2014, in Journal of the American Medical Association.

Related Links:
University of California, Los Angeles 
Agilent Technologies
Illumina